World Library  
Flag as Inappropriate
Email this Article

Linagliptin

Article Id: WHEBN0018475687
Reproduction Date:

Title: Linagliptin  
Author: World Heritage Encyclopedia
Language: English
Subject:
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Linagliptin

Linagliptin
Systematic (IUPAC) name
8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
Clinical data
Trade names Tradjenta, Trajenta
AHFS/Drugs.com
MedlinePlus
Licence data EMA:, US FDA:
Pregnancy cat.
Legal status
Routes Oral
Pharmacokinetic data
Bioavailability 30% oral
Protein binding 75% to 99% in plasma
Identifiers
CAS number  Y
ATC code A10
PubChem
ChemSpider  N
UNII  Y
KEGG  Y
ChEMBL  N
Chemical data
Formula C25H28N8O2 
Mol. mass 472.54 g/mol
 N   

Linagliptin (BI-1356, trade names Tradjenta (US), Trajenta (worldwide)) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.

Linagliptin (once-daily) was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type II diabetes.[1] It is being marketed by Boehringer Ingelheim and Lilly.

Mechanism of action

Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output. Thus, linagliptin stimulates the release of insulin in a glucose-dependent manner and decreases the levels of glucagon in the circulation.

Clinical trials

Results in 2010 from a Phase III clinical trial of linagliptin showed that the drug can effectively reduce blood sugar.[2]

Chemical Synthesis

Starting from commercially available 8-bromo-3-methylxanthine 1 linagliptin was prepared in four steps.[3] As part of a sequential alkylation sequence, xanthine derivative 1 was first N-alkylated with butyn-2-yl bromide in the presence of N,N-diisopropylethylamine followed by a second N-alkylation with (chloromethyl)-4-methylquinazoline 3 in the presence of potassium carbonate to furnish xanthine derivative 4. Subsequent nucleophilic aromatic substitution of the bromide in 4 with (R)-3-Boc-aminopiperidine followed by the Boc deprotection of the primary amine in 6 yielded linagliptin.

synthesis of linagliptin

References

  • H. Spreitzer (September 1, 2008). "Neue Wirkstoffe - BI-1356". Österreichische Apothekerzeitung (in German) (18/2008): 918. 
  • Wang, Y, Serradell, N, Rosa, E, Castaner, R (2008). "BI-1356". Drugs of the Future 33 (6): 473–477.  
  1. ^ "FDA Approves Type 2 Diabetes Drug from Boehringer Ingelheim and Lilly". 3 May 2011. 
  2. ^ "Four Phase III Trials Confirm Benefits of BI’s Oral, Once-Daily Type 2 Diabetes Therapy". Genetic Engineering & Biotechnology News. 28 June 2010. 
  3. ^ "8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes'". Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, Pfrengle W, Guth B, Lotz R, Sieger P, Fuchs H, Himmelsbach F Journal of Medicinal Chemistry; 2007; 50 pp 6450 - 6453; doi:10.1021/jm701280z

External links

  • Tradjenta official website (United States)
  • Trajenta (Australia)
  • Trajenta (Canada)
  • Trajenta (European Union)
  • Trajenta (India)
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.